Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 11,037	$ 17,116
Prepaid expenses and other current assets	606	827
Total Current Assets	11,643	17,943
Property and equipment, net	801	872
Deposits and other assets	23	23
Total Assets	12,467	18,838
Current Liabilities:
Accounts payable	1,493	2,020
Accrued expenses	1,058	1,526
Warrant liabilities	1,428	4,083
Accrued employee benefits	1,016	2,074
Deferred rent	92	90
Total Current Liabilities	5,087	9,793
Long term deferred rent	377	402
Total Liabilities	5,464	10,195
Stockholders' Deficit:
Common stock, $0.001 par value; 350,000,000 shares authorized, 128,648,365 issued and 128,566,886 outstanding	129	129
Additional paid-in capital	193,230	192,545
Accumulated deficit	(196,545)	(194,170)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit	(3,186)	(1,496)
Non-controlling interest	(1,923)	(1,914)
Total Stockholders' Deficit:	(5,109)	(3,410)
Total Liabilities and Stockholders' Deficit	12,467	18,838
Series A Preferred Stock [Member]
Current Liabilities:
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized,120,000 issued and outstanding	$ 12,112	$ 12,053